May 15, 2017 / 12:27 PM / 4 months ago

BRIEF-Otsuka, Teva sign licensing agreement for Japan on TEV-48125

May 15 (Reuters) - Otsuka Pharmaceutical Co

* Otsuka and Teva sign licensing agreement for Japan on prophylactic migraine drug candidate fremanezumab (TEV-48125)

* Teva Pharmaceutical Industries Ltd - with the agreement consummated, Otsuka is to pay Teva a lump-sum payment of $50 million

* Teva Pharmaceutical Industries Ltd - future clinical trials in Japan will be carried out and funded by Otsuka

* Teva Pharmaceutical Industries Ltd- in addition, Otsuka holds exclusive sales rights and will pay royalties on revenues to Teva

* Teva Pharmaceutical-through agreement, otsuka secures exclusive rights in japan to fremanezumab, which teva is globally developing in other countries Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below